PTK2 and melanoma: Hirata et al. showed that treatment with the BRAF inhibitor PLX4720 cascades integrin β1-FAK-Src signaling, which reactivates ERK and mitogen-activated protein kinase (MAPK) signaling in BRAF-mutant melanomas, resulting in melanoma-associated fibroblast-mediated ECM remodeling [205].